Investments
59Portfolio Exits
2Funds
2Coparion Web Traffic
Coparion Rank
Research containing Coparion
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Coparion in 3 CB Insights research briefs, most recently on Sep 20, 2019.
Latest Coparion News
Oct 15, 2021
Abalos Therapeutics , a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in Series A extension round. This additional round, which brings the total raised to date to €43m (USD50m), was led by Seventure Partners with participation from Coparion, Ventura BioMed Investors and Hx Bio Ventures as well as existing investors including Boehringer Ingelheim Venture Fund (BIVF), Gründerfonds Ruhr, NRW.BANK and High-Tech Gründerfonds (HTGF). In conjunction with the closing of the Series A financing round extension, Annegret de Baey from Seventure Partners and Sebastian Pünzeler from Coparion will join Abalos’ Supervisory Board. The company intends to use the funds to advance its first product candidate into a Phase 1/2 trial in multiple solid tumors including the expansion cohorts to demonstrate early signs of clinical efficacy as well as fund further pipeline expansion. Led by Dr. Marcus Kostka, CEO, Abalos Therapeutics is advancing a technology platform that harnesses the unique features of the lymphocytic choriomeningitis virus (LCMV), which specifically targets tumor cells. Through its proprietary Fast Evolution Platform, the company is generating variants with optimized anti-tumoral properties to trigger a highly precise and directed immune response that can be utilized for distant metastases and enable long-term disease control. FinSMEs 15/10/2021
Coparion Investments
59 Investments
Coparion has made 59 investments. Their latest investment was in Veertly as part of their Seed VC on October 10, 2021.
Coparion Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
10/25/2021 | Seed VC | Veertly | $2.21M | Yes | 1 | |
10/14/2021 | Series A - II | Abalos Therapeutics | $35.9M | Yes | 3 | |
10/1/2021 | Seed VC | emlen | $4.87M | Yes | Montan-Ventures-Saar, Undisclosed Angel Investors, and Undisclosed Investors | 3 |
8/25/2021 | Series B | |||||
6/28/2021 | Series B - II |
Date | 10/25/2021 | 10/14/2021 | 10/1/2021 | 8/25/2021 | 6/28/2021 |
|---|---|---|---|---|---|
Round | Seed VC | Series A - II | Seed VC | Series B | Series B - II |
Company | Veertly | Abalos Therapeutics | emlen | ||
Amount | $2.21M | $35.9M | $4.87M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Montan-Ventures-Saar, Undisclosed Angel Investors, and Undisclosed Investors | ||||
Sources | 1 | 3 | 3 |
Coparion Portfolio Exits
2 Portfolio Exits
Coparion has 2 portfolio exits. Their latest portfolio exit was FastBill on October 07, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/7/2021 | Acquired | 2 | |||
Date | 10/7/2021 | |
|---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 2 |
Coparion Fund History
2 Fund Histories
Coparion has 2 funds, including Coparion Fund I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
3/21/2018 | Coparion Fund I | $338.39M | 1 | ||
Coparion I |
Closing Date | 3/21/2018 | |
|---|---|---|
Fund | Coparion Fund I | Coparion I |
Fund Type | ||
Status | ||
Amount | $338.39M | |
Sources | 1 |
Coparion Team
5 Team Members
Coparion has 5 team members, including current Managing Director, Isabelle Canu.
Name | Work History | Title | Status |
|---|---|---|---|
Isabelle Canu | Managing Director | Current | |
Carsten Gellermann | Managing Director | Current | |
Christian R. Schulte | T-Mobile, Dexia Group, and Publicis Sapient | Managing Director | Current |
Christian Stein | Creathor Ventures | Managing Director | Current |
David Zimmer | Quadriga Capital, Altira Group, and T-Mobile | Managing Director | Current |
Name | Isabelle Canu | Carsten Gellermann | Christian R. Schulte | Christian Stein | David Zimmer |
|---|---|---|---|---|---|
Work History | T-Mobile, Dexia Group, and Publicis Sapient | Creathor Ventures | Quadriga Capital, Altira Group, and T-Mobile | ||
Title | Managing Director | Managing Director | Managing Director | Managing Director | Managing Director |
Status | Current | Current | Current | Current | Current |